Through this partnership, Orphalan will donate a supply of Cuvrior® to MAP International, a global humanitarian health organization with over 70 years of experience distributing critical medicines to communities in need.

This purchase order is to service US hospitals through BioPorto’s distribution relationship with Roche Diagnostics.

These studies shed light on the scientific controversy of whether activation of the Wnt/β-catenin pathway induces human stem cell pluripotency or differentiation.

“MERCURIUS™ Total DRUG-seq represents a new frontier in transcriptome-scale compound screening,” said Riccardo Dainese, CEO and Co-founder of Alithea Genomics. “We are empowering scientists to capture the full complexity of transcriptional responses—at a massive scale and with minimal cost. This product opens the door to discovering new biology, new targets, and new drugs faster than ever before.”

The new 133,500-square-foot headquarters at 12001 Exit 5 Parkway will house an advanced pharmacy featuring category III, 503A/503B compounding capabilities alongside integrated telemedicine services for peptide therapy management and prescription fulfillment.